TIMM Laboratory, Sahlgrenska Cancer Center, Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Hum Vaccin Immunother. 2020;16(1):109-111. doi: 10.1080/21645515.2019.1636598. Epub 2019 Jul 24.
Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) reduces the risk of relapse in the post-chemotherapy phase of acute myeloid leukemia (AML). Here we report the results of exploratory analyses of the clinical efficacy of HDC/IL-2 in AML with focus on the impact of karyotype aberrations in leukemic cells. Post-hoc analyses of phase III trial data suggested that HDC/IL-2 is primarily beneficial for patients with AML of normal karyotype. These results may be helpful in the selection of patients who are suitable for therapy and in the design of future immunotherapy protocols aiming at further defining the mechanism of relapse prevention by HDC/IL-2.
盐酸组胺和低剂量白细胞介素-2（HDC/IL-2）免疫疗法降低了急性髓系白血病（AML）化疗后复发的风险。在这里，我们报告了 HDC/IL-2 对 AML 的临床疗效的探索性分析结果，重点关注白血病细胞中染色体异常的影响。III 期试验数据的事后分析表明，HDC/IL-2 主要有益于正常核型的 AML 患者。这些结果可能有助于选择适合治疗的患者，并设计未来的免疫治疗方案，旨在进一步确定 HDC/IL-2 预防复发的机制。
